Image

Left Ventricular Unloading to Improve Outcome in Cardiogenic Shock Patients on VA-ECMO

Left Ventricular Unloading to Improve Outcome in Cardiogenic Shock Patients on VA-ECMO

Recruiting
18-80 years
All
Phase N/A

Powered by AI

Overview

Prospective, multi-center, randomized (1:1), controlled trial of Impella for active left ventricular unloading on top of veno-arterial extracorporeal membrane oxygenation vs. veno-arterial extracorporeal membrane oxygenation alone for the treatment of cardiogenic shock.

Description

In the past years extensive efforts in developing treatment strategies for patients with cardiogenic shock have been performed. One promising such strategy is active unloading of the left ventricle while simultaneously supporting the circulatory system with veno-arterial extracorporeal membrane oxygenation. Recently, in a multinational, multicenter, retrospective registry, it has been shown that this approach might be associated with lower mortality .

The investigators now seek to extend the evidence on this topic and to test this approach in a prospective, randomized, controlled, multicenter trial. A power calculation has been conducted based on the data from the registry. N=198 patients with cardiogenic shock will be randomized 1:1 to be either treated with an Impella for active left ventricular unloading on top of veno-arterial extracorporeal membrane oxygenation or with veno-arterial extracorporeal membrane oxygenation alone. A blinded interim analysis will be performed, which might lead to an adjustment of the enrollment target. The primary endpoint of this study will be death from any cause 30 days after randomization.

Eligibility

Inclusion Criteria:

Severe cardiogenic shock due to severe left ventricular dysfunction:

  • Systolic blood pressure <90 mmHg or need for catecholamines to maintain such blood pressure
  • Signs of impaired organ perfusion with at least one of the following: altered mental status OR cold, clammy skin OR oliguria with urine output <30 ml/h
  • Arterial lactate >5 mmol/l

Exclusion Criteria:

  • Post-cardiotomy cardiogenic shock.
  • Cardiogenic shock due to acute rejection in heart transplant recipients.
  • Obstructive cardiogenic shock (e.g. cardiogenic shock due to fulminant pulmonary embolism)
  • Cardiogenic shock due to other causes (e.g. bleeding, hypothermia)
  • Pre-existing Impella treatment.
  • Onset of shock >12 hours.
  • Mechanical complication of acute myocardial infarction.
  • Prolonged resuscitation (>60 minutes).
  • Severe peripheral artery disease with infeasibility for Impella or veno-arterial extracorporeal membrane oxygenation implantation.
  • Age <18 or >80 years.
  • Other severe concomitant disease with life expectancy <6 months.
  • Participation in another trial with an intervention or pregnancy.

Study details
    Cardiogenic Shock

NCT05577195

Universitätsklinikum Hamburg-Eppendorf

27 January 2024

Step 1 Get in touch with the nearest study center
We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

  Other languages supported:

First name*
Last name*
Email*
Phone number*
Other language

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.